Photoprotection compositions comprising chelating agents

Claim 2

A photoprotective composition useful for topical applica­tion characterized in that it comprises: (a) a safe and photoprotectively effective amount, pre­ferably from 1% to 10%, of chelating agent which exhibits at least a 50% inhibition of iron-catalyzed hydroxyl radical formation in the in vitro solution radical assay; and (b) a safe and effective amount of a topical carrier.

Claim 3

A photoprotective composition useful for topical appli­cation characterized in that it comprises: (a) a safe and photoprotectively effective amount, pre­ferably from 1% to 10%, of a chelating agent which exhibits at least a 20% reduction in skin wrinkle grade in the in vivo mouse skin wrinkling test; and (b) a safe and effective amount of a topical carrier.

Claim 4

A photoprotective composition useful for topical appli­cation characterized in that it comprises: (a) a safe and photoprotectively effective amount, pre­ferably from 1% to 10%, of a chelating agent which exhibits at least a 20% reduction in skin wrinkle grade in the in vivo mouse skin wrinkling test; and (b) a safe and effective amount of a topical carrier.

Claim 5

The composition of Claim 1 or 2 characterized in that the chelating agent is selected from: (a) an aromatic amine or a hydroxy aromatic amine selected from 2,2′-dipyridylamine; 1,10-phenanthroline; di-2-pyridyl­ketone; 2,3-bis(2-pyridyl)pyrazine; 2,3-bis(2-pyridyl)-5,6-­dihydropyrazine; 1,1′-carbonyldiimidazole; 2,4-bis(5,6-di­phenyl-1,2,4-triazine-3-yl)pyridine; 2,4,6-tri(2-pyridyl)-­1,3,5-triazine; 4,4′-dimethyl-2,2′-dipyridyl; 2,2′-biquinol­ine; di-2-pyridyl glyoxal; 2-(2-pyridyl)benzimidazole; 2,2′-bipyrazine; 3-(2-pyridyl)5,6-diphenyl-1,2,4-triazine; 3-(4-phenyl-2-pyridyl)-5-phenyl-1,2,4-triazine; 3-(4-phenyl-­2-pyridyl)-5,6-diphenyl-1,2,4-triazine; 2,3,4,6-tetrakis-(2′-­pyridyl)-pyrazine; 2,6-pyridinedicarboxylic acid; 2,4,5-tri­hydroxypyrimidine; phenyl 2-pyridyl ketoxime; 3-amino-5,6-­dimethyl-1,2,4-triazine; 6-hydroxy-2-phenyl-3(2H)-pyridazi­none; 2,4-pteridinediol; 2,2′dipyridyl; 2,3-dihydroxypyri­dine; and 5,7-dichloro-8-hydroxyquinoline; and analogs, homologs and isomers thereof; (b) a carbonyl or oximate selected from di-2-pyridilketone; 1,1′-carbonyldiimidazole; 2,2′-pyridil; 2-furildioxime; phenyl 2-pyridilketoxime; and 1,2-cyclohexanedione dioxime; and analogs, homologs and isomers thereof; (c) an amine selected from ethylenediamine-N,N-bis-(2-hy­droxyphenylacetic acid) dimethyl ester; diethyldithiocarbamic acid; 1-pyrrolidinecarbodithioic acid; and 3-amino-5,6-di­methyl-1,2,4-triazine; and analogs, homologs and isomers thereof; (d) a carboxylate, hydroxy acid, hydroxamate or aromatic hydroxy acid selected from 2,3-dihydroxybenzoic acid; 3-hy­droxy-5-(hydroxymethyl)-2-methyl-4-pyridine-carboxylic acid; ethylenediamine-N,N-bis-(2-hydroxyphenylacetic acid) dimethyl ester; 2,6-pyridinedicarboxylic acid; N-benzoyl-N-phenyl-hy­droxylamine; desferrioxamine B; 1-hydroxy-4-methyl-6-(2,4,4-­trimethylpentyl)-2(1H)-pyridone; 6-cyclohexyl-1-hydroxy-4-­methyl-2(1H)-pyridinone; and analogs, homologs and isomers thereof; (e) an alkoxide, enolate or ketoenolate selected from 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one; 3-hydroxy-5-(hy­droxymethyl)-2-methyl-4-pyridine-carboxylic acid; 1,2-di­methyl-3-hydroxypyrid-4-one; 3-hydroxy-2-methyl-4-pyrone; 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2-(1H)-pyridone; and 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone; and analogs, homologs and isomers thereof; (f) a phenoxide or catecholate selected from 1-hydroxy-4-­methyl-6-(2,4,4-trimethylpentyl)-2(1H)-pyridone; 6-hydroxy-­2-phenyl-3(2H)-pyridazinone; 6-cyclohexyl-1-hydroxy-4-­methyl-2-(1H)-pyridone; 2,3-dihydroxybenzoic acid; 4,5-di­hydroxy-1,3-benzene-disulfonic acid; ethylenediamine-N,N-­bis-(2-hydroxyphenylacetic acid) dimethyl ester; pyridoxic acid; 2,3-dihydroxypyridine; 2,4,5-trihydroxypyrimidine; 2,3-dihydroxynaphthalene; 5-hydroxy-2-(hydroxymethyl)-4H-py­ran-4-one; 2,3-dihydroxypyridine; 3-hydroxy-2-methyl-4-py­rone; 4-(2-amino-1-hydroxyethyl)-1,2-benzenediol; and ana­logs, homologs and isomers thereof; or (g) a mercaptide selected from diethyldithiocarbamaic acid; 1-pyrrolidinecarbodithioic acid; and analogs, homologs and isomers thereof.

Claim 6

A photoprotective composition useful for topical appli­cation characterized in that it comprises: (a) a safe and photoprotectively effective amount, pre­ferably 1% to 10%, of a chelating agent selected from 2,2′-­dipyridylamine; 1,10-phenanthroline; di-2-pyridylketone; 2-furildioxime; 2,3-bis(2-pyridyl)pyrazine; 1-hydroxy-4-­methyl-6-(2,4,4-trimethylpentyl)-2-(1H)-pyridone; 2,3-di­hydroxybenzoic acid; ethylenediamine-N,N-bis-(2-hydroxy­phenylacetic acid), dimethyl ester; 1,1′-carbonyldiimidazole; 1,2-dimethyl-3-hydroxypyrid-4-one; 2,4,5-tri(2-pyridyl)-­1,3,5-triazine; 1-pyrrolidinecarbodithioic acid; diethyl­dithiocarbamic acid; 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-­pyridone; 2,2′-dipyridyl; 1,2-cyclohexanedione dioxime; 3-hydroxy-2-methyl-4-pyrone; 2,3-bis(2-pyridyl)-5,6-dihydro­pyrazine; 3-(4-phenyl-2-pyridyl)-5-phenyl-1,2,4-triazine; 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one; 2,3-dihydroxy­pyridine; 2,2′-biquinoline; 2,2′-bipyrazine; 3-(2-pyridyl)-­5,6-diphenyl-1,2,4-triazine; 4,4′-dimethyl-2,2′-dipyridyl; 4,5-dihydroxy-1,3-benzene-disulfonic acid; phenyl 2-pyridyl ketoxime; desferrioxamine B; 3-hydroxy-5-(hydroxymethyl)-­2-methyl-4-pyridine-carboxylic acid; 5,7-dichloro-8-hydroxy­quinoline; 2,3-dihydroxynaphthalene; 2,3,5,6-tetrakis-(2′-­pyridyl)-pyrazine; 2,4-bis(5,6-diphenyl-1,2,4-triazine-3-­yl)pyridine; 2,2′-pyridil; 2-(2-pyridyl)benzimidazole; 6-hydroxy-2-phenyl-3(2H)-pyridazinone; 2,4-pteridinediol; 3-(4-phenyl-2-pyridyl)-5,6-diphenyl-1,2,4-triazine; N-ben­zoyl-N-phenyl-hydroxylamine; 3-amino-5,6-dimethyl-1,2,4-tri­azine; 2,6-pyridinedicarboxylic acid; and 2,4,5-trihydroxy­pyrimidine; and 4-(2-amino-1-hydroxyethyl)-1,2-benzenediol; preferably selected from 2,2′-dipyridylamine; 1,10-phenan­throline; di-2-pyridylketone; and 2-furildioxime; and 2,3-­bis(2-pyridyl)pyrazine; and (b) a safe and effective amount of a topical carrier.

Claim 7

A photoprotective composition useful for topical appli­cation characterized in that it comprises: (a) a safe and photoprotectively effective amount, pre­ferably 1% to 10%, of a chelating agent selected from 2,2′-­dipyridylamine; 1,10-phenanthroline; di-2-pyridylketone; 2-furildioxime; 2,3-bis(2-pyridyl)pyrazine; 1-hydroxy-4-­methyl-6-(2,4,4-trimethylpentyl)-2-(1H)-pyridone; 2,3-di­hydroxybenzoic acid; ethylenediamine-N,N-bis-(2-hydroxy­phenylacetic acid), dimethyl ester; 1,1′-carbonyldiimidazole; 1,2-dimethyl-3-hydroxypyrid-4-one; 2,4,5-tri(2-pyridyl)-­1,3,5-triazine; 1-pyrrolidinecarbodithioic acid; diethyl­dithiocarbamic acid; 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-­pyridone; 2,2′-dipyridyl; 1,2-cyclohexanedione dioxime; 3-hydroxy-2-methyl-4-pyrone; 2,3-bis(2-pyridyl)-5,6-dihydro­pyrazine; 3-(4-phenyl-2-pyridyl)-5-phenyl-1,2,4-triazine; 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one; 2,3-dihydroxy­pyridine; 2,2′-biquinoline; 2,2′-bipyrazine; 3-(2-pyridyl)-­5,6-diphenyl-1,2,4-triazine; 4,4′-dimethyl-2,2′-dipyridyl; 4,5-dihydroxy-1,3-benzene-disulfonic acid; phenyl 2-pyridyl ketoxime; desferrioxamine B; 3-hydroxy-5-(hydroxymethyl)-­2-methyl-4-pyridine-carboxylic acid; 5,7-dichloro-8-hydroxy­quinoline; 2,3-dihydroxynaphthalene; 2,3,5,6-tetrakis-(2′-­pyridyl)-pyrazine; 2,4-bis(5,6-diphenyl-1,2,4-triazine-3-­yl)pyridine; 2,2′-pyridil; 2-(2-pyridyl)benzimidazole; 6-hydroxy-2-phenyl-3(2H)-pyridazinone; 2,4-pteridinediol; 3-(4-phenyl-2-pyridyl)-5,6-diphenyl-1,2,4-triazine; N-ben­zoyl-N-phenyl-hydroxylamine; 3-amino-5,6-dimethyl-1,2,4-tri­azine; 2,6-pyridinedicarboxylic acid; and 2,4,5-trihydroxy­pyrimidine; and 4-(2-amino-1-hydroxyethyl)-1,2-benzenediol; preferably selected from 2,2′-dipyridylamine; 1,10-phenan­throline; di-2-pyridylketone; and 2-furildioxime; and 2,3-­bis(2-pyridyl)pyrazine; and (b) a safe and effective amount of a topical carrier.

Claim 8

The composition of Claims 1-4 characterized in that it additionally comprises a safe and photoprotectively effective amount of a sunscreening agent, preferably from 1% to 20% of a sunscreening agent selected from 2-ethylhexyl p-methoxycinnamate, butylmethoxydibenzoylmethane, 2-hydroxy-4-methoxybenzophenone, octyldimethyl p-aminobenzoic acid, the 4-N,N-(2-ethylhexyl)­methylaminobenzoic acid ester of 2,4-dihydroxybenzophenone, the N,N-di-(2-ethylhexyl)-4-aminobenzoic acid ester of 4-hydroxydi­benzoylmethane, the 4-N,N-(2-ethylhexyl)methylaminobenzoic acid ester of 4-hydroxydibenzoylmethane, the 4-N,N-(2-ethylhexyl)­methylaminobenzoic acid ester of 2-hydroxy-4-(2-hydroxyethoxy)­benzophenone, the 4-N,N-(2-ethylhexyl)methylaminobenzoic acid ester of 4-(2-hydroxyethoxy)dibenzoylmethane, the N-N-di-(2-­ethylhexyl)-4-aminobenzoic acid ester of 2-hydroxy-4-(2-hydroxy­ethoxy)benzophenone, the N,N-di-(2-ethylhexyl)-4-aminobenzoic acid ester of 4-(2-hydroxyethoxy)dibenzoylmethane and mixtures thereof.

Claim 9

The composition of Claims 1-5 characterized in that it additionally comprises a safe and photoprotectively effective amount of an anti-inflammatory agent, preferably from 0.1% to 10% of an anti-inflammatory agent selected from hydrocortisone, ibu­profen, naproxen, flufenamic acid, mefenamic acid, meclofenamic acid, piroxicam, felbinac, 4-(4′-pentyn-3′-one)-2,6,di- t -butyl­phenol, 4-(5′-hexynoyl)-2,6-di- t -butylphenol, 4-((S)-(-)-3′-­methyl-5′-hexynoyl)-2,6-di- t -butylphenol, 4-((R)(+)-3′-methyl-5′-­hexynoyl)-2,6-di- t -butylphenol, 4-(3′,3′-di- methoxypropionyl)-2, 6-di- t -butylphenol, Manjistha, Guggal and mixtures thereof.

Claim 10

The composition of Claims 1-6 characterized in that it additionally comprises a safe and photoprotectively effective amount of a radical scavenging compound, preferably from 1% to 5% tocophorol sorbate.

Claim 11

The use of a chelating agent which exhibits at least a 50% inhibition of iron-catalyzed radical formation in the in vitro solution radical assay, for the manufacture of a topical composition for inhibiting the deleterious effects of ultraviolet light exposure to skin, which composition is applied to the skin such that preferably from 0.001 mg/cm² to 1.0 mg/cm², more preferably from 0.01 mg/cm² to 0.1 mg/cm² of the chelating agent is applied to the skin.

Claim 12

The use of a chelating agent which exhibits at least a 50% inhibition of iron-catalyzed radical formation in the in vitro solution radical assay, for the manufacture of a topical composition for inhibiting the deleterious effects of ultraviolet light exposure to skin, which composition is applied to the skin such that preferably from 0.001 mg/cm² to 1.0 mg/cm², more preferably from 0.01 mg/cm² to 0.1 mg/cm² of the chelating agent is applied to the skin.

Claim 13

The use of a chelating agent which exhibits at least a 20% reduction in skin wrinkle grade in the in vivo mouse skin wrinkling test, for the manufacture of a topical composition for inhibiting the deleterious effects of ultraviolet light exposure to skin, which composition is applied to the skin such that preferably from 0.001 mg/cm² to 1.0 mg/cm², more preferably from 0.01 mg/cm² to 0.1 mg/cm² of the chelating agent is applied to the skin.

Claim 14

The use of a chelating agent which exhibits at least a 20% reduction in skin wrinkle grade in the in vivo mouse skin wrinkling test, for the manufacture of a topical composition for inhibiting the deleterious effects of ultraviolet light exposure to skin, which composition is applied to the skin such that preferably from 0.001 mg/cm² to 1.0 mg/cm², more preferably from 0.01 mg/cm² to 0.1 mg/cm² of the chelating agent is applied to the skin.

Claim 15

The use of Claim 8 or 9 characterized in that the chelating agent is selected from: (a) an aromatic amine or a hydroxy aromatic amine selected from 2,2′-dipyridylamine; 1,10-phenanthroline; di-2-pyridyl­ketone; 2,3-bis(2-pyridyl)pyrazine; 2,3-bis(2-pyridyl)-5,6-­dihydropyrazine; 1,1′-carbonyldiimidazole; 2,4-bis(5,6-di­phenyl-1,2,4-triazine-3-yl)pyridine; 2,4,6-tri(2-pyridyl)-­1,3,5-triazine; 4,4′-dimethyl-2,2′-dipyridyl; 2,2′-biquinol­ine; di-2-pyridyl glyoxal; 2-(2-pyridyl)benzimidazole; 2,2′-bipyrazine; 3-(2-pyridyl)5,6-diphenyl-1,2,4-triazine; 3-(4-phenyl-2-pyridyl)-5-phenyl-1,2,4-triazine; 3-(4-phenyl-­2-pyridyl)-5,6-diphenyl-1,2,4-triazine; 2,3,5,6-tetrakis-(2′-­pyridyl)-pyrazine; 2,6-pyridinedicarboxylic acid; 2,4,5-tri­hydroxypyrimidine; phenyl 2-pyridyl ketoxime; 3-amino-5,6-­dimethyl-1,2,4-triazine; 6-hydroxy-2-phenyl-3(2H)-pyridazi­none; 2,4-pteridinediol; 2,2′dipyridyl; 2,3-dihydroxypyri­dine; and 5,7-dichloro-8-hydroxyquinoline; and analogs, homologs and isomers thereof; (b) a carbonyl or oximate selected from di-2-pyridilketone; 1,1′-carbonyldiimidazole; 2,2′-pyridil; 2-furildioxime; phenyl 2-pyridilketoxime; and 1,2-cyclohexanedione dioxime; and analogs, homologs and isomers thereof; (c) an amine selected from ethylenediamine-N,N-bis(2-hy­droxyphenylacetic acid) dimethyl ester; diethyldithiocarbamic acid; 1-pyrrolidinecarbodithioic acid; and 3-amino-5,6-di­methyl-1,2,4-triazine; and analogs, homologs and isomers thereof; (d) a carboxylate, hydroxy acid, hydroxamate or aromatic hydroxy acid selected from 2,3-dihydroxybenzoic acid; 3-hy­droxy-5-(hydroxymethyl)-2-methyl-4-pyridine-carboxylic acid; ethylenediamine-N,N-bis-(2-hydroxyphenylacetic acid) dimethyl ester; 2,6-pyridinedicarboxylic acid; N-benzoyl-N-phenyl-hy­droxylamine; desferrioxamine B; 1-hydroxy-4-methyl-6-(2,4,4-­trimethylpentyl)-2-(1H)-pyridone; 6-cyclohexyl-1-hydroxy-4-­methyl-2(1H)-pyridinone; and analogs, homologs and isomers thereof; (e) an alkoxide, enolate or ketoenolate selected from 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one; 3-hydroxy-5-(hy­droxymethyl)-2-methyl-4-pyridine-carboxylic acid; 1,2-di­methyl-3-hydroxypyrid-4-one; 3-hydroxy-2-methyl-4-pyrone; 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2-(1H)-pyridone; and 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone; and analogs, homologs and isomers thereof; (f) a phenoxide or catecholate selected from 1-hydroxy-4-­methyl-6-(2,4,4-trimethylpentyl)-2(1H)-pyridone; 6-hydroxy-­2-phenyl-3(2H)-pyridazinone; 6-cyclohexyl-1-hydroxy-4-­methyl-2(1H)-pyridone; 2,3-dihydroxybenzoic acid; 4,5-di­hydroxy-1,3-benzene-disulfonic acid; ethylenediamine-N,N-­bis-(2-hydroxyphenylacetic acid) dimethyl ester; pyridoxic acid; 2,3-dihydroxypyridine; 2,4,5-trihydroxypyrimidine; 2,3-dihydroxynaphthalene; 5-hydroxy-2-(hydroxymethyl)-4H-py­ran-4-one; 2,3-dihydroxypyridine; 3-hydroxy-2-methyl-4-py­rone; 4-(2-amino-1-hydroxyethyl)-1,2-benzenediol; and ana­logs, homologs and isomers thereof; or (g) a mercaptide selected from diethyldithiocarbamaic acid; 1-pyrrolidinecarbodithioic acid; and analogs, homologs and isomers thereof.

Claim 16

The use of a chelating agent selected from 2,2′-di­pyridylamine; 1,10-phenanthroline; di-2-pyridylketone; 2-furil­dioxime; 2,3-bis(2-pyridyl)pyrazine; 1-hydroxy-4-methyl-6-(2,4,4-­trimethylpentyl)-2(1H)-pyridone; 2,3-dihydroxybenzoic acid; ethylenediamine-N,N-bis-(2-hydroxy-phenylacetic acid), dimethyl ester; 1,1′-carbonyldiimidazole; 1,2-dimethyl-3-hydroxypyrid-­4-one; 2,4,5-tri(2-pyridyl)-1,3,5-triazine; 1-pyrrolidinecarbodi­thioic acid; diethyldithiocarbamic acid; 6-cyclohexyl-1-hydroxy-­4-methyl-2(1H)-pyridone; 2,2′-dipyridyl; 1,2-cyclohexanedione dioxime; 3-hydroxy-2-methyl-4-pyrone; 2,3-bis(2-pyridyl)-5,6-­dihydropyrazine; 3-(4-phenyl-2-pyridyl)-5-pyenyl-1,2,4-triazine; 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one; 2,3-dihydroxypyridine; 2,2′-biquinoline; 2,2′-bipyrazine; 3-(2-pyridyl)-5,6-diphenyl-­1,2,4-triazine; 4,4′-dimethyl-2,2′dipyridyl; 4,5-dihydroxy-1,3-­benzene-disulfonic acid; phenyl 2-pyridyl ketoxime; desferriox­amine B; 3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridine­carboxylic acid; 5,7-dichloro-8-hydroxyquinoline; 2,3-dihydroxy­naphthalene; 2,3,5,6-tetrakis-(2′-pyridyl)-pyrazine; 2,4-bis-­(5,6-diphenyl-1,2,4-triazine-3-yl)pyridine; 2,2′-pyridil; 2-(2-­pyridyl)benzimidazole; 6-hydroxy-2-phenyl-3(2H)-pyridazinone; 2,4-­pteridinediol; 3-(4-phenyl-2-pyridyl)-5,6-diphenyl-1,2,4-triazine; N-benzoyl-N-phenyl-hydroxylamine, 3-amino-5,6-dimethyl-1,2,4-­triazine; 2,6-pyridinedicarboxylic acid; 2,4,5-trihydroxy­pyrimidine; and 4-(2-amino-1-hydroxyethyl)-1,2-benzenediol; preferably selected from 2,2′-dipyridylamine; 1,10-phenanthroline; di-2-pyridylketone; and 2-furildioxime, 2,3-bis(2-pyridyl)-­pyrazine, for the manufacture of a topical composition for inhibiting the deleterious effects of ultraviolet light exposure to skin, which composition is applied to the skin such that preferably from 0.001 mg/cm² to 1.0 mg/cm², more preferably from 0.01 mg/cm² to 0.1 mg/cm² of the chelating agent is applied to the skin.

Claim 17

The use of a chelating agent selected from 2,2′-di­pyridylamine; 1,10-phenanthroline; di-2-pyridylketone; 2-furil­dioxime; 2,3-bis(2-pyridyl)pyrazine; 1-hydroxy-4-methyl-6-(2,4,4-­trimethylpentyl)-2(1H)-pyridone; 2,3-dihydroxybenzoic acid; ethylenediamine-N,N-bis-(2-hydroxy-phenylacetic acid), dimethyl ester; 1,1′-carbonyldiimidazole; 1,2-dimethyl-3-hydroxypyrid-­4-one; 2,4,5-tri(2-pyridyl)-1,3,5-triazine; 1-pyrrolidinecarbodi­thioic acid; diethyldithiocarbamic acid; 6-cyclohexyl-1-hydroxy-­4-methyl-2(1H)-pyridone; 2,2′-dipyridyl; 1,2-cyclohexanedione dioxime; 3-hydroxy-2-methyl-4-pyrone; 2,3-bis(2-pyridyl)-5,6-­dihydropyrazine; 3-(4-phenyl-2-pyridyl)-5-pyenyl-1,2,4-triazine; 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one; 2,3-dihydroxypyridine; 2,2′-biquinoline; 2,2′-bipyrazine; 3-(2-pyridyl)-5,6-diphenyl-­1,2,4-triazine; 4,4′-dimethyl-2,2′dipyridyl; 4,5-dihydroxy-1,3-­benzene-disulfonic acid; phenyl 2-pyridyl ketoxime; desferriox­amine B; 3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridine­carboxylic acid; 5,7-dichloro-8-hydroxyquinoline; 2,3-dihydroxy­naphthalene; 2,3,5,6-tetrakis-(2′-pyridyl)-pyrazine; 2,4-bis-­(5,6-diphenyl-1,2,4-triazine-3-yl)pyridine; 2,2′-pyridil; 2-(2-­pyridyl)benzimidazole; 6-hydroxy-2-phenyl-3(2H)-pyridazinone; 2,4-­pteridinediol; 3-(4-phenyl-2-pyridyl)-5,6-diphenyl-1,2,4-triazine; N-benzoyl-N-phenyl-hydroxylamine, 3-amino-5,6-dimethyl-1,2,4-­triazine; 2,6-pyridinedicarboxylic acid; 2,4,5-trihydroxy­pyrimidine; and 4-(2-amino-1-hydroxyethyl)-1,2-benzenediol; preferably selected from 2,2′-dipyridylamine; 1,10-phenanthroline; di-2-pyridylketone; and 2-furildioxime, 2,3-bis(2-pyridyl)-­pyrazine, for the manufacture of a topical composition for inhibiting the deleterious effects of ultraviolet light exposure to skin, which composition is applied to the skin such that preferably from 0.001 mg/cm² to 1.0 mg/cm², more preferably from 0.01 mg/cm² to 0.1 mg/cm² of the chelating agent is applied to the skin.

Claim 18

The use of Claims 8-11 characterized in that the composition also comprises a safe and photoprotectively effective amount of a sunscreening agent, preferably selected from 2-ethyl­hexyl p-methoxycinnamate, butylmethoxydibenzoylmethane, 2-hydroxy-­ 4-methoxybenzophenone, octyldimethyl p-aminobenzoic acid, the 4-N,N-(2-ethylhexyl)methylaminobenzoic acid ester of 2,4-di­hydroxybenzophenone, the N,N-di-(2-ethylhexyl)-4-aminobenzoic acid ester of 4-hydroxydibenzoylmethane, the 4-N,N-(2-ethylhexyl)­methylaminobenzoic acid ester of 4-hydroxydibenzoylmethane, the 4-N,N-(2-ethylhexyl)methylaminobenzoic acid ester of 2-hydroxy-­4-(2-hydroxyethoxy)benzophenone, the 4-N,N-(2-ethylhexyl)methyl­aminobenzoic acid ester of 4-(2-hydroxyethoxy)dibenzoylmethane, the N-N-di-(2-ethylhexyl)-4-aminobenzoic acid ester of 2-hy­droxy-4-(2-hydroxyethoxy)benzophenone, the N,N-di-(2-ethylhexyl)-­4-aminobenzoic acid ester of 4-(2-hydroxyethoxy)dibenzoylmethane and mixtures thereof, such that preferably from 0.01 mg/cm² to 1.0 mg/cm², more preferably from 0.05 mg/cm² to 0.5 mg/cm² of the sunscreening agent is applied to the skin.